Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Lynda F. Voigt"'
Autor:
Jennifer A. Doherty, Mary Anne Rossing, Noel S. Weiss, Amanda I. Phipps, Chu Chen, Lynda F. Voigt, Shirley A.A. Beresford, Deirdre A. Hill
Publikováno v:
Cancer Causes & Control. 22:1639-1646
The daily administered dose of progestin in continuous-combined estrogen-progestin therapy is provided to counteract the proliferative effect of estrogen on the postmenopausal endometrium. However, there remains some uncertainty as to whether use of
Autor:
J. Lee Nelson, Linda Bley, Janet R. Daling, Carin E. Dugowson, Thomas D. Koepsell, Lynda F. Voigt
Publikováno v:
Arthritis & Rheumatism. 34:1502-1507
As part of a prospective case-control study of newly diagnosed rheumatoid arthritis (RA) in women, we identified all cases of probable, definite, or classic RA diagnosed in 1987-1989 in 18-64-year-old women who were members of a health maintenance or
Autor:
Kelly Ehrlich, Lynda F. Voigt, Rochelle L. Garcia, Susan D. Reed, Noel S. Weiss, Meira Epplein, Kristen Upson, Elizabeth M. Swisher, Kimberly H. Allison, Katherine M. Newton, C. Diana Jordan
Publikováno v:
Obstetrics & Gynecology. 116:365-373
Limited data exist to inform clinicians and patients as to the likelihood of long-term endometrial hyperplasia response to progestin therapy, especially for atypical hyperplasia. We evaluated women with complex and atypical endometrial hyperplasia, c
Publikováno v:
Cancer Causes & Control. 20:1779-1782
To document incidence rates of vulvar cancer, specifically invasive vulvar cancer, from 1973 to 2004 in the United States.Nine US cancer registries from the Surveillance, Epidemiology, and End Results (SEER) databases were used to identify women aged
Autor:
Noel S. Weiss, Susan D. Reed, Lynda F. Voigt, Katherine M. Newton, Meira Epplein, Victoria L. Holt
Publikováno v:
Annals of Epidemiology. 19:1-7
Purpose We sought to examine the relationship between recent use of oral contraceptives and hormone therapy and endometrial hyperplasia (EH) risk. Methods Cases comprised women diagnosed with complex EH ( n = 289) or atypical EH ( n = 173) between 19
Autor:
Susan D. Reed, Lynda F. Voigt, Rochelle L. Garcia, Carolyn D. Jordan, Kimberly H. Allison, Kathryn M. Newton
Publikováno v:
American Journal of Surgical Pathology. 32:691-698
Current World Health Organization classification of endometrial hyperplasia is problematic because of poor diagnostic reproducibility. We sought to determine factors that cause diagnostic disagreement in a review of 2601 endometrial specimens. Blinde
Autor:
Noel S. Weiss, Jennifer A. Doherty, Jocelyn M. Weiss, Cornelia M. Ulrich, Lynda F. Voigt, Chu Chen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 14:2524-2530
Exposure to estrogens is a likely cause of endometrial cancer, but the means by which estrogens exert this effect are not entirely clear. One hypothesis is that certain estrogen metabolites bind to the DNA, forming bulky adducts that damage the DNA a
Autor:
Mary Anne Rossing, Jennifer A. Doherty, Stephen M. Schwartz, John R. Houck, Douglas A. Dightman, Noel S. Weiss, Lynda F. Voigt, Chu Chen, Robert J. Freeman, Perry J. Thornton
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 14:357-366
2-Hydroxylated metabolites of estrogen have been shown to have antiangiogenic effects and inhibit tumor cell proliferation, whereas 4-hydroxylated metabolites have been implicated in carcinogenesis. We examined whether polymorphisms in certain genes
Autor:
Shirley A.A. Beresford, Susan D. Reed, Noel S. Weiss, Lynda F. Voigt, Deirdre A. Hill, Jennifer A. Doherty
Publikováno v:
American Journal of Obstetrics and Gynecology. 191:1146-1151
Progestogens are given to diminish the risk of endometrial cancer (ECA) observed with postmenopausal estrogen therapy. The pattern of progestogen administration and number of days that the progestogen is given per month appear to affect ECA risk. We
Autor:
S. Kay Lewis, Noel S. Weiss, Lynda F. Voigt, Chu Chen, Annette L. Fitzpatrick, Stephen R. Plymate
Publikováno v:
Cancer. 103:76-84
BACKGROUND There have been several epidemiologic studies investigating the association between circulating levels of insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and insulin in relation to the risk of